Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 17, 2026 16:35 ET | Source: Celularity Inc.

Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

FLORHAM PARK, N.J., April 17, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a longevity-focused regenerative and cellular medicine company, today announced that on April...
April 17, 2026 16:20 ET | Source: Lincoln Educational Services Corporation

Lincoln Educational Services Corporation Schedules First Quarter 2026 Earnings Release And Conference Call

PARSIPPANY, N.J., April 17, 2026 (GLOBE NEWSWIRE) -- Lincoln Educational Services Corporation (Nasdaq: LINC) (“Lincoln”) announced today that it will host a conference call to discuss its first...
April 17, 2026 16:15 ET | Source: BGIN Blockchain Limited

BGIN BLOCKCHAIN LIMITED Schedules the Fiscal Year 2025 Earnings and Conference Call on April 24, 2026

SINGAPORE, April 18, 2026 (GLOBE NEWSWIRE) -- BGIN BLOCKCHAIN LIMITED (the “Company”; NASDAQ: BGIN), a digital asset technology company with proprietary cryptocurrency mining technologies and a...
April 17, 2026 16:15 ET | Source: Zenas BioPharma

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in...
April 17, 2026 16:10 ET | Source: TTEC Services Corporation

TTEC Schedules First Quarter 2026 Earnings Release and Webcast of Investor Conference Call

TTEC Schedules First Quarter 2026 Earnings Release and Webcast of Investor Conference Call
April 17, 2026 16:05 ET | Source: Pyxis Oncology

Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026

Mouse analog of MICVO (maMICVO) monotherapy produced dose-dependent inhibition of tumor growth in a syngeneic preclinical model of HNSCC maMICVO monotherapy modulated the tumor-immune environment in...
April 17, 2026 16:05 ET | Source: ORIC Pharmaceuticals

ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 17, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that...
April 17, 2026 16:05 ET | Source: SEALSQ

SEALSQ Announces Agenda of its 2026 Annual General Meeting of Shareholders

Geneva, Switzerland, April 17, 2026 (GLOBE NEWSWIRE) -- SEALSQ Corp (“SEALSQ” or “the Company”) (NASDAQ: LAES), a company that focuses on developing and selling Semiconductors, PKI, and Post-Quantum...
April 17, 2026 16:05 ET | Source: 4D Molecular Therapeutics, Inc.

4DMT Announces New Employment Inducement Grants

EMERYVILLE, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and...
April 17, 2026 16:05 ET | Source: ALX Oncology

ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

SOUTH SAN FRANCISCO, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel...